What is Distek?
Distek operates at the intersection of precision engineering and life sciences, delivering a sophisticated suite of instruments designed for dissolution testing, media preparation, and advanced bioprocessing. The company's portfolio, which includes the BIOne single-use bioreactor and the BIOne 1250 control system, serves a diverse clientele ranging from global pharmaceutical manufacturers and biosimilar developers to academic research institutions. With a legacy of innovation dating back to its ISO certification in 1976, Distek maintains a competitive edge through a deep patent portfolio and a commitment to user-centric design. Their instruments are essential for ensuring content uniformity and regulatory compliance in complex drug manufacturing workflows, positioning the firm as a foundational partner in the global supply chain for therapeutic development.
How much funding has Distek raised?
Distek has raised a total of $2.4M across 2 funding rounds:
Debt
$1M
Debt
$1.4M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.4M led by PPP
Key Investors in Distek
PPP
Public-Private Partnership
What's next for Distek?
With the recent influx of capital, Distek is well-positioned to accelerate its R&D initiatives, particularly in the expansion of its bioprocessing and single-use technology segments. The strategic focus will likely center on scaling production capabilities to meet the rising demand for mammalian and microbial cell culture solutions. Furthermore, the company is expected to enhance its digital integration features, ensuring that its instrumentation remains at the forefront of the industry's transition toward automated, data-driven laboratory environments. By prioritizing technological modernization and market penetration, Distek aims to reinforce its status as a premier provider of high-performance analytical tools, effectively navigating the evolving landscape of global pharmaceutical manufacturing and quality assurance.
See full Distek company page
